The European Society of Cardiology Cardiac Resynchronization Therapy Survey II: A comparison of cardiac resynchronization therapy implantation practice in Europe and France.

[1]  L. Fauchier,et al.  Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients. , 2019, European heart journal.

[2]  J. González-Juanatey,et al.  Cardiac resynchronization therapy outcomes in patients under nonoptimal medical therapy , 2018, Journal of arrhythmia.

[3]  J. Ruskin,et al.  Utilization and in-hospital complications of cardiac resynchronization therapy: trends in the United States from 2003 to 2013 , 2017, European heart journal.

[4]  C. Aquilante,et al.  Medication regimen complexity in ambulatory older adults with heart failure , 2017, Clinical interventions in aging.

[5]  J. Taieb,et al.  Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators: Groupe de Rythmologie et Stimulation Cardiaque de la Société Française de Cardiologie and Société Française de Gériatrie et Gérontologie. , 2016, Archives of cardiovascular diseases.

[6]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[7]  J. Daubert,et al.  Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study , 2015, European heart journal.

[8]  L. Fauchier,et al.  Effect of age on survival and causes of death after primary prevention implantable cardioverter-defibrillator implantation. , 2015, The American journal of cardiology.

[9]  M. Falagas,et al.  Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[10]  G. Hindricks,et al.  European cardiac resynchronization therapy survey II: rationale and design. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[11]  Katja Zeppenfeld,et al.  Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association. , 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  William T. Abraham,et al.  Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex , 2013 .

[13]  G. Wells,et al.  Impact of QRS Morphology and Duration on Outcomes After Cardiac Resynchronization Therapy: Results From the Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) , 2013, Circulation. Heart failure.

[14]  Jeroen J. Bax,et al.  2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, European heart journal.

[15]  Christophe Leclercq,et al.  2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[16]  A. Oto,et al.  Permanent Pacemaker and Implantable Cardioverter Defibrillator Infections: Seven Years of Diagnostic and Therapeutic Experience of a Single Center , 2010, Clinical cardiology.

[17]  Eugene Crystal,et al.  Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. , 2010, Journal of the American College of Cardiology.

[18]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[19]  M. Gold,et al.  Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. , 2009, Journal of the American College of Cardiology.

[20]  K. Dickstein,et al.  The European cardiac resynchronization therapy survey. , 2009, European heart journal.

[21]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[22]  D. Delurgio,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[23]  J. Daubert,et al.  Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. , 2001, The New England journal of medicine.